Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious

BACKGROUND: A median progression free survival (PFS) of 18–20 months and median overall survival (OS) of 51–57 months can be achieved with the use of imatinib, in metastatic or advanced gastrointestinal stromal tumor (GIST). Sunitinib and regorafenib are approved options for patients progressing on...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Gastrointest Oncol
Main Authors: Ramaswamy, Anant, Pande, Nikhil, Shetty, Omshree, Shetty, Nitin, Gupta, Sudeep, Ostwal, Vikas
Formato: Artigo
Idioma:Inglês
Publicado: AME Publishing Company 2016
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4963378/
https://ncbi.nlm.nih.gov/pubmed/27563456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.03.06
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares